Evotec said it has established a dedicated R&D site for gene therapy-based projects that will start operations in Orth/Donau, Austria. It said the launch of Evotec Gene Therapy "marks an important step towards [our] long-term vision of becoming a fully modality-agnostic drug discovery and development partnership company."
CEO Werner Lanthaler noted that "in recent years, precision medicines based on cell and gene therapies have emerged and are predicted to grow significantly." He added "we are delighted to initiate our new gene therapy platform and step into this field, which perfectly fits into our business strategy going forward."
According to Evotec, its team in Austria have expertise in vectorology and virology, as well as disease insights, notably in haemophilia, haematology, metabolic and muscle diseases. It added that the fully operational R&D site will enable Evotec to "perform dedicated services in the field of gene therapy along the value chain of its customers from pharma and biotech, as well as foundations and academia."
The news coincides with Evotec announcing earlier this week a multi-year gene therapy alliance with Takeda. Under the partnership, Evotec said it will support several Takeda programmes targeting conditions aligned with the Japanese drugmaker's core therapeutic areas of oncology, rare diseases, neuroscience and gastroenterology.
To read more Top Story articles, click here.